Drugs / NITROARGININE
NITROARGININE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01324115 | Apr 2011 → Sep 2012 | cancer of unknown primary site | Cancer Research UK | Terminated | No outcome recorded Stop: Business |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NITROARGININE | ChEMBL registry synonym — accepted as the source's own label CHEMBL227744 ↗ |
| Known as | L-ng-nitroarginine | ChEMBL registry synonym — accepted as the source's own label CHEMBL227744 ↗ |
| Known as | L-NNA | “Patients receive a single dose of NG-nitro-L-arginine (L-NNA) IV over 10 minutes on day 1.” NCT01324115 ↗ |
| Known as | NG-nitro-L-arginine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01324115 ↗ |
| Known as | NSC-53662 | ChEMBL registry synonym — accepted as the source's own label CHEMBL227744 ↗ |
| Action | Inhibit | “a Nitric Oxide Synthase Inhibitor” NCT01324115 ↗ |
| Modality | Small molecule | — CHEMBL227744 ↗ |
| Route | Intravenous | “Patients receive a single dose of NG-nitro-L-arginine (L-NNA) IV over 10 minutes on day 1.” NCT01324115 ↗ |